Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

NCT05552157 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05552157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
Lead sponsor
Washington University School of Medicine
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 22, 2024
Completion date
August 30, 2034
Enrollment
280 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease, alzheimers disease, familial, dementia